“This leaves Intercept, Galectin, Biking and Cyt
Post# of 148167
(Total Views: 562)
Posted On: 05/11/2020 7:54:02 PM
“This leaves Intercept, Galectin, Biking and CytoDyn still in the race. NASH is a VERY difficult condition to treat and the winner will take a very large price ($20B-$35B).
This makes our NASH proof-of-concept study much more valuable.”
The 1 question that I proposed this morning for the web conference on Wednesday is in regards to the status of the second NASH study that CYDY initiated a few months ago (the study that netted a $1 billion licensing deal). My question is much more relevant now that the NASH drug possibility has been thinned with this failed drugged. Even a NASH licensing deal involving leronlimab for $500 million, or $100 million, could have an upfront payment that could fund CYDY for a couple of months up to a year.
Again, I propose we ask about the NASH study.
This makes our NASH proof-of-concept study much more valuable.”
The 1 question that I proposed this morning for the web conference on Wednesday is in regards to the status of the second NASH study that CYDY initiated a few months ago (the study that netted a $1 billion licensing deal). My question is much more relevant now that the NASH drug possibility has been thinned with this failed drugged. Even a NASH licensing deal involving leronlimab for $500 million, or $100 million, could have an upfront payment that could fund CYDY for a couple of months up to a year.
Again, I propose we ask about the NASH study.
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼